transparent gif


Ej inloggad.

Göteborgs universitets publikationer

Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years.

Författare och institution:
Ronald Dahl (-); Alexander Kapp (-); Giselda Colombo (-); Jan G R de Monchy (-); Sabina Rak (Institutionen för medicin, avdelningen för invärtesmedicin); Waltraud Emminger (-); Bente Riis (-); Pernille M Gr?nager (-); Stephen R Durham (-)
Publicerad i:
The Journal of allergy and clinical immunology, 121 ( 2 ) s. 512-518.e2
Artikel, refereegranskad vetenskaplig
Sammanfattning (abstract):
BACKGROUND: This is an interim analysis of a randomized, double-blind, placebo-controlled phase III trial with 3 years of daily treatment with grass tablet immunotherapy (GRAZAX; ALK-Abell? A/S, H?rsholm, Denmark) or placebo, followed by 2 years of follow-up to assess the persistent efficacy. OBJECTIVE: We sought to evaluate the efficacy and safety of specific immunotherapy with grass allergen tablets compared with placebo after treatment covering 2 consecutive grass pollen seasons. METHODS: The interim analyses included 351 adult participants with moderate-to-severe allergic rhinoconjunctivitis caused by grass pollen. Participants were treated with active (n = 189) or placebo (n = 162) tablets for an average of 22 months. All participants were allowed to use symptomatic rescue medication. RESULTS: The primary efficacy analysis showed highly significant mean reductions of 36% in rhinoconjunctivitis symptom score (P < .0001; median reduction, 44%) and 46% in rhinoconjunctivitis medication score (P < .0001; median reduction, 73%) in the active group relative to the placebo group. Mean rhinoconjunctivitis quality of life was 33% better (P < .0001; median, 40%). Clinical improvements were paralleled by significant changes in allergen-specific immunoglobulins. The treatment was well tolerated, and adverse events led to withdrawal in less than 1% of participants. There were no serious adverse events related to treatment. CONCLUSION: Grass allergen tablet immunotherapy showed progressive immunologic changes and highly significant efficacy over 2 years of continued treatment.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Klinisk medicin ->
Postens nummer:
Posten skapad:
2008-02-14 08:00
Posten ändrad:
2010-01-26 11:04

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007